The MGC Pharmaceuticals (ASX:MXC) share price soared 20% today. Here's why

The cannabis company's shares finished the week on a high note…

| More on:
Lab worker puts hands in the air and dances around

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The MGC Pharmaceuticals Ltd (ASX: MXC) share price smoked the market today. This comes after the company provided investors with a positive update regarding its clinically tested nutritional supplement, ArtemiC Rescue.

At the closing bell, the cannabis company's shares finished up 19.51% at 4.9 cents apiece.

What did MGC Pharma announce?

Investors are pushing up the MGC Pharmaceuticals share price following the news the company has expanded its sales base.

In the release, MGC Pharma advised it has secured an import approval permit for ArtemiC Rescue by Indian regulators.

This enables the importation, distribution, marketing, and sales of ArtemiC Rescue in India, generating the company a new revenue stream.

A small trial batch had been previously sent for proof of concept with its local partner, Carino Water Solutions & Energy.

The sample passed all the required regulatory hurdles and was granted a Food Safety and Standards Authority of India licence. Additionally, it also cleared Indian Customs' import requirements, resulting in the approval for the sale of ArtemiC Rescue across India.

Gaining authorisation to the Indian market is a milestone given it has the world's second-largest population.

ArtemiC Rescue has been clinically demonstrated to alleviate moderate symptoms for patients suffering from COVID-19.

MGC Pharma noted the approvals are a major step forward in the pathway for global sales of ArtemiC Rescue.

Furthermore, the company stated it is making progress on the long-term development of its investigational medicinal product, CimetrA.

An application for Emergency Use Authorisation in India as well as other national regulatory and medical agencies are underway. This includes seeking approval from the United States Food and Drug Administration (FDA) to treat patients in the United States.

What did management say?

Commenting on the news driving up the MGC Pharmaceuticals share price, co-founder and managing director Roby Zomer said:

We are proud of achieving the milestone of being granted Indian import and distribution approval for of ArtemiC Rescue, and are pleased to have the opportunity to alleviate the symptoms of COVID-19 in one of the largest populated countries in the world.

Whilst the virus continues to mutate, as we have seen with Omicron, MGC Pharma is well placed to offer a solution on a worldwide scale to ease the pressure on national healthcare systems and aid the economic recovery of jurisdictions who have been widely affected by the pandemic.

About the MGC Pharma share price

In the past 12 months, the MGC Pharmaceuticals share price has accelerated by almost 90%. However, most of those gains came in the early part of 2021, before the company's shares moved sideways.

On valuation grounds, MGC Pharma has a market capitalisation of roughly $132.23 million, with more than 2.70 billion shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »